Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Withdrawn | |||
Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
Venclexta | Venetoclax | Withdrawn | ||||
Adcetris | Brentuximab vedotin | Withdrawn | ||||
Adcetris | brentuximab vedotin | Hodgkin lymphoma | Withdrawn | |||
Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Active | |||
Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active |